CPT 81437: Hereditary Neuroendocrine Tumor Gene Panel
Commercial payers pay $784 on average nationally for this procedure.
CPT code 81437 describes a genomic sequence analysis panel that evaluates a patient specimen for sequence variants and copy number variants across at least five genes associated with hereditary neuroendocrine tumor syndromes; this is a molecular diagnostic panel typically performed by clinical molecular laboratories and reported for genetic diagnostic testing using blood or tissue specimens, with the typical site of service being a clinical laboratory or reference molecular diagnostics facility.
For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.
Customize your policy alerts
Sign up for cpt 81437 policy alerts
Get alerted when payer policies referencing 81437 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial pricing for CPT 81437 centers around a BUCA average of $784.30, reflecting a broad mid-market commercial benchmark. Blue Cross Blue Shield shows the highest mean and wide tail values, while Aetna and UnitedHealth Group sit lower on central tendency. Cigna’s mean is elevated with a substantial upper-end presence. These patterns suggest a market where some national payers push rates well above the BUCA average while others cluster closer to or below it.
Dispersion (P75 minus P25) highlights variability across payers: Blue Cross Blue Shield has the widest interquartile spread at $570.40 ($1,327.30 - $755.90), indicating the largest mid-market variability. Cigna follows with a spread of $914.20? Wait recalc: Cigna P75 $1,168.30 minus P25 $285.10 equals $883.20; Aetna’s spread is $156.40, UnitedHealth Group’s spread is $255.60, and BUCA’s spread is $515.60. Thus, Cigna and Blue Cross Blue Shield show the widest dispersion, while Aetna is the tightest.